FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that sequesters T-cells to lymph nodes through functional antagonism of sphingosine-1-phosphate 1 receptor. FTY720 also demonstrates aproven efficacy in multiple in vitro and in vivo cancer models, suggesting a potential therapeutic role in cancer patients. A potential anticancer mechanism of FTY720is through the inhibition of sphingosine kinase 1, a proto-oncogene with in vitro and clinical cancer association. In addition, FTY720's anticancer properties may be attributable to actions on several other molecular targets. This study focuses onreviewing the emerging evidence regarding the anticancer properties and moleculartargets of FTY720. While the clinical transition of FTY720 is currently limited by it simmune suppression effects, studies aiming at FTY720 delivery and release together with identifying its key synergetic combinations and relevant patient subsets maylead to its rapid introduction into the clinic.
White, C., Alshaker, H., Cooper, C., Winkler, M., & Pchejetski, D. (2016). The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget, 7(17), 23106–23127. https://doi.org/10.18632/oncotarget.7145